Catalent (Novo Holdings) vs Lonza: CDMO Comparison
How does Catalent (Novo Holdings) compare to Lonza for AAV manufacturing?
Side-by-side comparison of Catalent (Novo Holdings) and Lonza on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Lonza holds 3 active EMA GMP certificates; Catalent (Novo Holdings) does not appear in EudraGMDP.
- Lonza maintains 5 MHRA / UK GMP certificates; Catalent (Novo Holdings) does not.
On a 13-modality CDMO landscape, both Catalent (Novo Holdings) and Lonza qualify as AAV manufacturers; Lonza carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Catalent (Novo Holdings) and Lonza qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Catalent (Novo Holdings) vs Lonza
How does Catalent (Novo Holdings) compare to Lonza for AAV manufacturing?
On CDMO Signal's composite Signal Score, Catalent (Novo Holdings) is 75/100 and Lonza is 78/100; Catalent (Novo Holdings) has 1 FDA inspection on record vs 2 for Lonza; European coverage is 0 active EMA+MHRA certificates for Catalent (Novo Holdings) vs 8 for Lonza. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Catalent (Novo Holdings) or Lonza?
Both Catalent (Novo Holdings) and Lonza maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Catalent (Novo Holdings) has 1 FDA inspection on record; Lonza has 2.
How do Catalent (Novo Holdings) and Lonza compare on European GMP coverage?
Catalent (Novo Holdings) holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Lonza holds 3 active EMA GMP certificates and 5 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Catalent (Novo Holdings) or Lonza?
Catalent (Novo Holdings) is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Lonza is matched to 1. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for AAV manufacturing — Catalent (Novo Holdings) or Lonza?
Both Catalent (Novo Holdings) and Lonza are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →